Aquestive Therapeutics, Inc. (AQST) Stock

Aquestive Therapeutics, Inc. (AQST) is a Healthcare stock trading at $4.71 (as of 2026-06-18), with a market capitalization of $505.56M and a trailing P/E of -6.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Aquestive Therapeutics, Inc. is a pharmaceutical company that identifies, develops, and commercializes products focused on treating conditions in the United States and internationally. Its marketed therapies include Sympazan, Suboxone, Zuplenz, and Azstarys, and it also develops additional proprietary product candidates in areas such as seizures and amyotrophic lateral sclerosis.

Valuation — source: SEC EDGAR (first-party)
Price	$4.71
Market Cap	$505.56M
P/E Ratio	-6.8
EV / EBITDA	-8.3
Price / Book	-15.36
Price / Sales	10.41
DCF Value (model)	$-6.77
DCF Upside vs Price	-243.7%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$44.55M
Net Margin	-188.1%
Return on Equity	202.4%
Debt / Equity	-1.32
Current Ratio	4.10
Revenue Growth (YoY)	-22.6%
EPS Growth (YoY)	52.9%
FCF Growth (YoY)	47.5%

Financial Health — source: SEC EDGAR
Altman Z-Score	-2.55 (distress)
Piotroski F-Score	2/9 (weak)

Valuation vs Sector & Industry
Stock P/E	-6.8
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-132.6%
vs Industry	-139.6%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Bratton Capital Management, L.P. ($40.72M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Daniel Barber
Employees	142
Country	US
IPO Date	2018-07-25

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.